Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 6,100
Avg Vol 26,092
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 37%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a...

Phone: 650-422-7515
Address:
960 San Antonio Road, Palo Alto, United States
Latest News on SMNRW
No data available.